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Treatment of melanoma remains a challenge in advanced
disease. Recently, the molecular differentiation in BRAF-
mutated, NRAS-mutated and c-kit-mutated melanomas led
to new treatment strategies. Different trials show that
imatinib or nilotinib lead to meaningful responses in c-kit-
mutated melanoma patients. There are little published data
on sequential inhibition using these two drugs in melanoma.
We describe the sequential use of imatinib after nilotinib in a
c-kit-mutated melanoma patient, who progressed on
interferon, Allovectin, dacarbazine, nilotinib and ipilimumab,
and was finally treated with the c-kit inhibitor imatinib. From
July 2011 to September 2011, the patient received
ipilimumab (four doses with 3mg/kg). Clinical assessment
after immunotherapy showed disease progression.
Therefore, a treatment change to imatinib 800mg daily was
made from February 2012 to May 2013. Under this
treatment, the patient showed a partial response as per the
RECIST criteria. The present lesions continued responding
(computed tomography scans: May 2012–March 2013).
Unfortunately, in October 2012, new brain metastases
developed. Nevertheless, the use of c-kit inhibitors in c-kit-
mutated melanoma patients seems to be a promising
treatment option. Furthermore, a delayed response to
ipilimumab after 6 months could also have led to or
supported the partial response in this case. However, when
two biologically similar compounds are administered in a
melanoma patient and the tumour mass shows progressive
disease upon administration of the first agent, an additional
progression with no effect may be expected when the
second one is used. This case shows, in contrast, that the
use of imatinib after progression upon nilotinib can be
beneficial. Melanoma Res 27:396–398 Copyright © 2017
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
The differentiation of melanoma in BRAF-mutated, NRAS-
mutated and c-kit-mutated melanomas recently led to new
treatment perspectives and strategies [1,2]. Kit is expressed
in up to 3% of all melanomas [3] and the c-kit mutation
is present in about 40% of mucosal and in 5% of acral
melanomas [4]. Mucosal vulvovaginal melanomas have the
highest frequency of these mutations [5,6]. C-kit inhibitors,
such as imatinib and nilotinib, can target c-kit mutations [7].
Hodi et al. [7] reported that imatinib (400mg administered
once or twice daily) can be effective in c-kit-mutated
melanoma.Moreover, Tran et al. [3] suggest that the second-
generation tyrosine kinase inhibitor nilotinib is a promising
agent in the treatment of metastatic melanoma harbouring
the kit mutation. Several phase II clinical trials are ongoing
to further investigate its efficacy.
Only little data on the sequential inhibition with these two
drugs in advanced melanoma are available so far [8]. Here,
we describe the sequential use of imatinib after nilotinib in
a patient with advanced c-kit-mutated melanoma.
Patients and methods
A 56-year-old female patient with an ulcerated acrolentigi-
nous melanoma with a Breslow tumour thickness of 2mm
on the lateral nail wall on the dig I of the right foot
underwent primary excision, followed by a wide excision.
Because of a local recurrence 1 year later, she was referred
to the University Hospital of Zurich, where surgical revision
of the local satellites and the sentinel lymph node biopsy
not carried out previously were performed. Because of the
histological evidence of a lymph node micrometastasis (1/3),
lymph node dissection and an adjuvant treatment with
pegylated interferon (100 μg subcutaneously weekly) were
implemented from September 2009 to January 2010
(Rozati, 2013 #3380). The mutation analysis detected a c-kit
mutation on exon 13 (K642F).
Upon progression with new skin metastasis on the right
leg, the patient was included in a clinical phase III trial
(registered at clinicaltrials.gov, NCT01028222) and was
treated intralesionally with 2 mg allovectin-7, a sterile
bicistronic plasmid DNA encoding the human major
histocompatibility complex class I HLA-B7 protein and
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β2-microglobulin protein that was injected into a single
lesion weekly for 6 consecutive weeks and repeated
every 8 weeks [9]. After documented progression
4 months later, the patient was included in another ran-
domized, phase II, open-label, multicentre, two-arm
study comparing the efficacy of Tasigna (nilotinib)
(Novartis Pharma Schweiz AG, Rotkreuz, Switzerland)
versus dacarbazine (DTIC) in c-kit-mutated melanoma
patients. First, the patient was treated with DTIC
850 mg/m2 every 3 weeks for 12 weeks. Then, upon
crossover, the patient received nilotinib 400 mg twice
daily according to the protocol for 6 months from January
to June 2011. Dose reduction to 200 mg once daily for
5 weeks and dose interruption for 1 week were necessary
because of increases in lipase and amylase. New lung
metastases were then detected and the patient was
excluded from the trial because of progressive disease.
Thereafter, the patient was treated with four infusions of
ipilimumab intravenously 3mg/kg every 3 weeks. This was
the only checkpoint inhibitor available at that time in
Switzerland. The clinical assessment of the right leg after
immunotherapy again showed a clear disease progression.
As this young female patient with c-kit-mutated melanoma
progressed upon interferon, Allovectin (Vical Incorporated,
San Diego, California, USA), DTIC, nilotinib and anti-
CTLA-4 treatment, we decided on the first-generation
tyrosine kinase inhibitor Glivec (imatinib) (Novartis
Pharma Schweiz AG) as compassionate use. The patient
was treated with imatinib 800mg orally daily, showing a
partial response as per the RECIST criteria. The present
lesions continued responding (computed tomography scans
May 2012 to March 2013). Certainly, also a delayed
response to ipilimumab after 6 months could have led to or
supported this response. Unfortunately, in October 2012,
new brain metastases developed.
They were simultaneously treated with whole-brain
irradiation with a total of 30 (3× 10) Gy and steroids
(dexamethasone, initially 12mg, then 4mg daily). With
this additional treatment, the disease was stabilized for
another 6 months. The patient eventually died in May
2013 after epileptic seizures in March 2013 and April 2013.
Discussion
We report on a 56-year-old female patient who was
initially treated for 17 weeks with the c-kit inhibitor
nilotinib and after several treatment failures (interferon,
Allovectin, DTIC, nilotinib and ipilimumab) responded
to imatinib for 68 weeks until she died in May 2013.
Although the patient experienced adverse events under
the treatment with nilotinib that required dose reduction,
the treatment with imatinib was tolerated very well. After
36 weeks of treatment, new brain metastases developed.
They could be controlled for 32 weeks using steroids for
detumescence and whole-brain irradiation. Development
of brain metastases during the treatment with imatinib is
a typical feature due to the inability for imatinib to pass
through the brain–blood barrier [10].
However, the use of tyrosine kinase inhibitors in c-kit-
mutated melanoma patients seems to be a promising
treatment option [8,11,12]. More precisely, in a phase II
clinical trial with 43 c-kit-mutated melanoma patients
treated with imatinib administered 400 mg/day, the
median progression-free survival was 3.5 months and the
6-month progression-free survival rate was 36.6%. One-
year overall survival rate was 51% and the overall
response rate was 23.3% [13]. Complete responses in
metastatic c-kit-mutated melanoma with imatinib were
also reported [8,14,15].
In an open-label, single-centre trial in Korea, nine
patients (3/9 with kit mutation in exon 11 and 6/9 with kit
amplification) were treated with nilotinib 800 mg/day.
Two of the treated patients, both with the kit mutation,
achieved a partial response and five patients achieved
stable disease, indicating the potential of treatment [16].
Larger clinical trials with nilotinib are ongoing to further
determine its efficacy in metastatic melanoma. So far,
successful nilotinib treatment after imatinib progression
has been published in a small melanoma cohort [17] and
in chronic myelogenous leukaemia (CML) [12,18,19].
Our case shows that the inverse administration that is, the
use of imatinib after progression upon nilotinib and ipi-
limumab in melanoma can lead to good clinical and
radiological results. This is in agreement with published
data on nilotinib-resistant and imatinib-resistant cell lines
that provide a rationale for treating patients with melan-
oma progressing on imatinib or nilotinib with alternative
tyrosine kinase inhibitors in vitro [8]. Furthermore, Guo
et al. [13] describe the best response rates to imatinib in
melanomas harbouring the c-kit mutation in exon 11 and
13, as was the case in our patient.
Resistance to imatinib and nilotinib has been reported
frequently [8,11,12,18]. Development of therapeutic
resistance to imatinib might be caused by NRAS muta-
tions and kit copy number [7]. Camgoz et al. [18] studied
nilotinib-resistant cells and described an upregulation of
antiapoptotic BCR/ABL, GCS and SK-1 genes and the
MRP1 transporter gene and downregulation of apoptotic
Bax and CerS1 genes. This suggests that the develop-
ment of resistance mechanisms to nilotinib and imatinib
might be different and could explain why our patient
responded to imatinib after progression upon nilotinib.
Another possible explanation is the intermittent admin-
istration of the two tyrosine kinase inhibitors to reduce
drug resistance development as Das Thakur et al. [20]
reported for vemurafenib. Furthermore, our patient
received ipilimumab between the two treatments.
Upregulation of T cell activity might play a role in gen-
erating better results of further targeted therapies. This is
supported in other case reports, in agreement with
Balakan et al. [21], where the selective BRAF inhibitor
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vemurafenib was administered after ipilimumab in a
patient with brain metastases with good response; we
believe that the sequential administration may have
contributed towards the good imatinib outcome. In
addition, similar findings were observed in a large phase
III trial for NRAS mutant patients treated with MEK
inhibitors [22]. The administration of ipilimumab with a
subsequent increase in the activity of the immune system
could play a role in the stabilization of the disease. A
further explanation in this specific case for the better and
more durable response to imatinib than to nilotinib could
be the better side-effect profile [13]. This can lead to a
better dose and treatment management and a higher
plasma level. In our patient, the dose of nilotinib had to
be reduced because of adverse events and might have led
to reduced efficacy. In addition, the presence of a higher
tumour load with progressive metastasis could implicate
an increased concentration of c-kit-mutated tumour cells,
where the use of the second c-kit inhibitor might lead to
better results.
In CML patients, nilotinib shows better response rates
compared with imatinib. Moreover, dasatinib, another
second-generation tyrosine kinase inhibitor, shows good
efficacy when used upon progression after nilotinib and
imatinib in CML patients [12]. However, preliminary data
show minimal efficacy in unselected melanomas and poor
tolerance [19,23]. It would be interesting to learn more
about possible new treatment strategies in c-kit-mutated
melanoma. This is a case report and it is therefore not
possible to draw general conclusions. Furthermore, data
were not collected prospectively and were not standardized
as in a clinical trial setting. However, the incidence of this
type of melanoma is low and this renders the realization of
a large clinical trial difficult.
In this case, we observed a clear benefit of imatinib after the
administration of nilotinib and ipilimumab in c-kit-mutated
melanoma. Certainly, we have to underline that a delayed
response to ipilimumab after 6 months could have also led to
or supported the partial response in this case. Yet, we believe
that the therapies discussed could be a good treatment
strategy in c-kit-mutated melanoma and therefore plan to
treat more patients to support the observed trend. The
approach outlined in this case report should be assessed in a
larger cohort and should be studied further.
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